1.
Hum Vaccin Immunother
; 17(10): 3511-3514, 2021 10 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34152898
RESUMO
This was a phase I/II study testing the feasibility of a vaccine by autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) in elderly acute myeloid leukemia (AML) patients in first or second complete remission. Pulsed DC were administered at doses of 9 × 106 subcutaneously (1 mL) and 1 × 106 intra-dermally (0.1 mL). Five doses of vaccine were planned on days +1 + 7 + 14 + 21 and +35. Five DC-vaccines were produced and injected for all five patients included in the study. No severe adverse event was documented. Larger Phase 2 studies are now required to precise the role of DC-vaccines with leukemic apoptotic bodies in older as well as younger AML populations. (Clinicaltrials.gov NCT01146262).
Assuntos
Vacinas Anticâncer , Leucemia Mieloide Aguda , Idoso , Cadáver , Células Dendríticas , Estudos de Viabilidade , Humanos , Leucemia Mieloide Aguda/terapia
2.
Bone Marrow Transplant
; 53(8): 1044-1047, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29391525